GENEMAX CORPORATION (OTCBB: GMXX) (FRANKFURT AND BERLIN EXCHANGES: GX1)

Today we're covering a company with a great story to tell. A story about commercialization and a story about human compassion. At StockUpticks, we try to feature companies that combine a profit-motivate with an interest in a better quality of life for everyone. That's GeneMax in a proverbial nutshell. The company is developing therapeutics for the treatment of cancer based on its proprietary TAP technology that restores the ability of the immune system to recognize and attack cancerous cells.

A vaccine. That's right, a cancer vaccine. As you'll discover in this profile, the research is in place, the people are in place, the patent and licenses are in place and human trials will begin in the near future. Most importantly, the central GeneMax partner in this breakthrough is none other than the University of British Columbia and that simply says credibility.

A lot of medical insiders are excited about GeneMax coming of age and the company received national media coverage on the ABC News television program "Business Now" on June 16, 2003. (If you would like to view the broadcast, simply go to the GeneMax online homepage by clicking here.  The broadcast is available with a click of your mouse.) And speaking of mice (of a different form) in animal trials 70% of mice treated with the Tap Vaccine remained tumor free, while 100% of the untreated mice died of multiple tumors within 50 days!  There is a lot more testing to be done, but early results seem to point to a product that could be amazingly effective.

GeneMax is a very liquid stock trading near its yearly low. That, coupled with its recent media coverage and its proximity to human trials for its core product, makes us think there is no better time than now to bring this company to your attention. 
 

ABOUT GENEMAX CORPORATION (www.genemax.com)

GeneMax Corporation is a product-focused biotechnology company that is applying discoveries in cellular immunology and cancer biology to the development of proprietary therapeutics for cancer and immunological diseases. The Company intends to develop and bring to market novel therapeutics that treat diseases modulated by the immune system, including cancer, autoimmune diseases and transplant rejection. 

The Company's technologies are based on an understanding of the function of a protein  "pump"  within cells that is essential in the processing of tumor antigens, known as Transporters associated with Antigen Processing ("TAP").

The GeneMax core focus is on commercialization of the TAP technology as the basis for cancer vaccines. GeneMax holds the worldwide license to the patented TAP technologies that were discovered and developed by GeneMax's Chairman and Chief Science Officer, Dr. Wilfred Jefferies and his team of researchers at the University of British Columbia Biomedical Research Center. 

To review a printable GeneMax Fact Sheet in Adobe PDF format, click here.
If you need to download a free copy of Adobe Reader to access the PDF Fact Sheet, click here.
 

THE GENEMAX STRATEGIC VISION

The Company's strategic vision is to be a product-driven  biotechnology company,  focusing  primarily on use of its patented TAP  technology and related technologies to restore the TAP function  within  cancerous  cells,  thus making them  immunogenic. As a result,  the MHC Class I Proteins, which is defined as when cancers are not able to cause an immune response because they no longer express key immune proteins on their cell surface (known as "MHC Class I Proteins"), can signal the immune system to attack the cancer. 
A

The Company intends to develop the TAP technology as a therapeutic  cancer vaccine that will restore normal  immune  recognition. GeneMax management believes that its cancer vaccine is the only  therapeutic approach that addresses this  problem of "non-immunogenicity" of cancer.

GENEMAX PRODUCTS

The TAP Cancer Vaccine is targeted at those cancers that are deficient in the TAP protein, which include commonly occurring breast cancer,  prostate cancer,  lung cancer,  liver cancer, melanoma, renal cancer and colorectal cancer. This could include a broad group of cancers, up to 60% of tumor-specific cancers (the most common cancers). 

The TAP Cancer Vaccine would deliver the TAP protein and genetic information,  thus "turning on" the defective TAP signaling system within the cancer cells. These cancer cells would then transport cancer antigen proteins to the cell surface using the individual's specific MHC Class I proteins. 

As a result, the immune response would be targeted to the entire repertoire of cancer antigen proteins  produced by the cancer cell, rather than just to the single cancer antigen (as delivered by usage of current cancer vaccines).  The TAP Cancer Vaccine would allow the immune response to respond to the cancer even if the TAP protein and genetic information is only delivered to a small portion of the cancer cells. Once sensitized by those cancer cells that have had the TAP system reactivated, the immune system will attack all of the tumor cells with even low levels of TAP expression and effectively kill the cancer with the patients own T-Cells.

In addition, the TAP Cancer Vaccine would generate a strong immune response to any TAP-deficient cancer, regardless of the patient's individual genetic  variability either in the MHC Class I proteins or in the cancer-specific proteins.

IN THE RESEARCH PIPELINE

THE MARKET FOR TAP AND ITS COMPETITIVE ADVANTAGES

The "proof of principle" for TAP as a cancer vaccine was established in research conducted over the last 10 years. Results of a series of animal studies using TAP were published in Nature Biotechnology in May 2000. The TAP vaccine is now ready for formal preclinical testing that is required before submitting an Investigational New Drug application to Health Canada or the FDA.
 

In test trials, up to 70% of mice receiving cancer cells transfected with the TAP vaccine remained tumor free. 100% of the untreated mice  died of multiple tumors within 50 days.

The second leading cause of mortality in the U.S. is cancer, attributed to 500,000 deaths annually. With the aging population, the National Cancer Institute expects cancer to become the leading cause of death within 5 years.  Frost and Sullivan forecast a U.S. $2 billion market for cancer vaccines by 2007, with a compounded annual growth rate of 104%. GeneMax believes the TAP cancer vaccine could secure a significant portion of this large growth market.
 

THE GENEMAX SCIENTIFIC ADVISORY BOARD & DIRECTORS

Julia Levy, Ph.D., Chairman of the Scientific Advisory Board, is the former CEO of QLT Inc. It was during her time at QLT that the company received FDA approval for its Visudyne(TM) therapy to treat age-related Macular Degenration of the eyes. She received her Ph.D. in immunology from the University of London and Dr. Levy has received a long list of awards and homors related to immunology. James C. Hogg, M.D., Ph.D., is one of Canada's leading lung pathologists and holds the position of Professor, Pathology and Laboratory Medicine, University of British Columbia. Victor Ling, Ph.D. is Vice President, Research at the B.C. Cancer Agency and BC Cancer Research Center and holds the position of Assistant Dean, Cancer Research at the University of British Columbia. Bernard Moss, M.D., Ph.D., is currently the Laboratory Chief, Genetic Engineering Section, Laboratory of Viral Diseases, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Maryland. Karl Eric Hellstrom, M.D., Ph.D., is a world-reknown expert on immunology with credentials from the Karolinska Institute in Stockholm, Sweden and the University of Washington Medical School. 

Wilfred Jefferies, D. Phil (Oxon), Charman of the Board and Chief Science Officer of Genemax
Ronald L. Handford, B.A. Sc., M.B.A., President and CEO of GeneMax
Karl Eric Hellstrom, M.D., Ph.D., member of the Scientific Advisory Board of GeneMax
 

THE GENEMAX TIMELINE AND DELIVERY TO MARKET

• 1994 - UBC applied for TAP patent
• 1996 - UBC applied for Assay patent
• 1998 - UBC granted Assay patent
• March, 2000 - GeneMax and UBC sign license agreements (UBC had invested $1.5 million into the technologies at this point)
• April, 2002 - Patent received on lead product TAP-1 

• 2003 - Preclinical
• 2004 - Begin Phase I and seek partnership associations and possible licensing deals with other companies
• 2005 - Phase II*
• 2006 - 2007 - Phase III*
• 2008 and Beyond - Begin Commercialization*

INVESTMENT CONSIDERATIONS

Biotech deals have taken center stage since the Internet bubble burst in April of 2000.  A tremendous amount of money is now available for hot biotech properties.  Of course some will reach the finish line and some won't -- but for those that do, a huge reward awaits.  And GeneMax has the apparent potential to be something other than a "me too" product.  A vaccine to treat the most common forms of cancer would cause a stir in the medical community of a rare magnitude.  Such a stir would likely be quickly followed by the financial community.  GeneMax is a very liquid stock trading near its yearly low. That, coupled with its recent media coverage and its proximity to human trials for its core product, makes us think there is no better time than now to bring this company to your attention. 
 

GMXX SELECTED FINANCIAL HIGHLIGHTS

For a current quote on GMXX, click here.

For GMXX SEC filings, click here.
 

CONTACT

GeneMax Corporation (OTCBB: GMXX) (Frankfurt and Berlin Exchanges: GX1)

Toll Free Investor Communications: 866.872.0077
Local Phone: 360.332.7734
For a PowerPoint Investor Presentation at the GeneMax Web site, click here.

---

Want to feature YOUR company to over 1 MILLION investors?
Click here to learn more about our programs or email us directly at info@stockupticks.com

Disclaimer: StockUpTicks.com is a property of Market Pathways Financial Relations Incorporated (MP).  The information, opinions and analysis contained herein are based on sources believed to be reliable but no representation, expressed or implied, is made as to its accuracy, completeness or correctness.  Past performance is no guarantee of future results. This report is a paid advertisement and is for information purposes only and should not be used as the basis for any investment decision. MP has been compensated $15,000 by Investor Communications for preparation and distribution of this report and other advertising services.This constitutes a conflict of interest as to MP’s ability to remain objective in its communication regarding the subject company.  Write or call MP for detailed disclosure as required by Rule 17b of the Securities Act of 1933/1934.  MP is not an investment advisor and this report is not investment advice. This information is neither a solicitation to buy nor an offer to sell securities but is a paid advertisement.  Information contained herein contains forward-looking statements and is subject to significant risks and uncertainties, which will affect the results.  The opinions contained herein reflect our current judgment and are subject to change without notice. MP and/or its affiliates, associates and employees from time to time may have either a long or short position in securities mentioned.  Information contained herein may not be reproduced in whole or in part without the express written consent of Market Pathways Financial Relations Incorporated.